AzTrials
AzTrials

Heart FailurePhase 4NCT04334447

Implementing Standards of Care for Heart Failure Patients in General Practice - A Regional Disease Management Program

A Phase 4 study testing Improved primary care HF diagnostics, Heart Failure education and Structured transitional protocol planning post-discharge care in people with Heart Failure, run by KU Leuven at 1 site in Belgium.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Heart failure (HF) is an important health problem. Most chronic HF management occurs in primary care. Although guidelines exist, there is an important implementation gap in current HF care in Belgium. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Heart Failure
What is being tested?
Improved primary care HF diagnostics, Heart Failure education and Structured transitional protocol planning post-discharge care
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteBelgium
Study dates
4 Nov 2019to 31 Jul 2022
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of HF

Who cannot join

  • No pre-specified exclusion criteria

Trial locations and contacts

1 site in 1 country.

Belgium1 site, 1 recruiting
  • Academisch Centrum Huisartsgeneeskunde

    Leuven, Vlaams-Brabant, 3000

    Willem Raat, 016 37 66 21, willem.raat@kuleuven.be

    Recruiting

Other trials in Belgium

About this study

Heart failure (HF) is an important health problem. Most chronic HF management occurs in primary care. Although guidelines exist, there is an important implementation gap in current HF care in Belgium. We will conduct a non-randomized, non-controlled prospective observational trial to implement guideline-recommended best clinical practices in primary care in Leuven, a region of ± 100.000 inhabitants. These best clinical practices include education of general practitioners, access to natriuretic peptides and audits in the electronic health record (EHR), training and implementation of HF educators in primary care and a structured post-discharge transition process . The main objective is to implement best clinical practices in a dynamic way and study the implementation process. We will evaluate the implementation of several guideline-recommended best clinical practices to optimize the diagnosis and treatment of heart failure in a real-world primary care setting.

Read the detailed description

The primary objective of this study is to establish a dynamic implementation environment for HF management in Leuven. It is not a primary objective to study the effect of various best clinical practices on the defined outcomes. We focus on the evolution in quality of HF management through an evaluation of the implementation process. Specific research questions are as follows:

  1. Do HF education and a learning environment improve the GPs' self-efficacy?
  2. Does reimbursement of the NT-proBNP test lead to implementation?
  3. How do primary care professionals and patients experience the introduction of a primary care HF educator?
  4. What is the adoption rate of a HF discharge checklist in hospitals' EHR? How do care professionals adhere to a checklist-supported structured discharge protocol?
  5. What is the feasibility of implementing automated audits in GPs EHR?
  6. Does this implementation study affect regional levels of HF hospitalization and readmissions?

Outcomes

Measurements at baseline We will register contact data (telephone number and/or mail address), and sociodemographic variables (age, sex and type of HF ) for patients who receive a HF educator contact and give informed consent. If it is an education-session post-discharge, we will ask if the patient had a contact with his/her GP.

We record patients' relevant risk criteria at discharge in the checklist.

We will record all yearly HF hospitalizations of patients in Groot-Leuven in the regional hospitals of UZ Leuven and Heilig Hart as our primary outcome for effectiveness (aggregated data). Secondary outcomes will be the number of yearly emergency room visits for HF and HF readmissions within 30 days. We will also extract these data for the previous 5 years, starting from 01.01.2014 to establish a time-series trend.

Process Evaluation

We will investigate the intervention implementation in a process evaluation. On a population level, we will look at yearly echocardiographies and cardiology consultations as a process indicator. In participating practices, we will monitor the number of registered HF diagnoses in the GPs EHR (coded or free-text). Process evaluation for specific guideline-recommended practices is as follows:

GP education GPs need to complete an online questionnaire before and after the web-based mandatory training session. The questionnaire assesses GP self-efficacy in the diagnosis and management of heart failure.

NT-proBNP We will look at the number of tests conducted per participating physician and the total number of tests performed in the largest regional lab (MCH Leuven).

HF educator We will register the number of conducted HF educator contacts and patient self-efficacy and quality of life at baseline and after 6 months as scored by the EHFScB-9 and SF-12 questionnaires respectively. We will perform a qualitative analysis of primary care professions' (GP , HF nurse, HF educator) and patients' experience of the introduction of this new role through semi-structured interviews.

Structured transitional protocol We will measure the total number of transitional contacts by proxy: the HF nurse in the hospital will fill in a standardized checklist in the EHR. Outcomes are the number of completed checklists and HF educator contacts after discharge. The HF educator verifies whether high-risk patients who gave informed consent saw their GP at the education session post-discharge.

Automated EHR audits We will record the proportion of HF patients with a registered left ventricular ejection fraction in the EHR, as well as the proportion of HFrEF patients with guideline-recommended medication (RAAS-blockade/B-blocker/MRA). We will look at the proportion of HF patients who had at least one contact with their GP in the last six months.

Data collection

At the patient level We will collect individual patient data for patients referred for a primary care HF educator consultation (by the GP or as part of the structured transmural protocol). Inclusion requires informed consent. The HF nurse will fill out a registration form with level of referral (GP or HF nurse in the hospital), contact information, sociodemographic data and an EHFScB-9 questionnaire assessing self-efficacy. We will repeat the questionnaire after 6 months via telephone or mail. The HF educator will record whether high-risk patients who gave informed consent saw their GP at the education session post-discharge.

At the care profession level We will collect the number of NT-proBNP tests at the participating lab. A yearly audit in the GPs EHR will record registered diagnoses and audit-specific outcomes.

At the population level (Groot-Leuven) Data collection for the primary outcome occurs at the hospital level through data already collected as part of the mandatory Minimale Ziekenhuisgegevens (MZG) registration for the population of Groot-Leuven (i.e. postal codes 3000, 3001, 3010, 3012, 3018, 3050). As part of the MZG registration, hospitals need to classify hospital stays according to diagnosis. Reimbursement of the hospital stay is dependent on the number of primary and secondary coded diagnoses. We define a HF hospitalization as a hospitalization with ICD-10 code I50 as the primary diagnosis. Data collection for echocardiographies and cardiology consultations occurs at the level of the Intermutual Agency (IMA). IMA is in charge of collecting administrative and medical data for all patients who have national health insurance.

For the transitional contact, we will collect the aggregated number of checklists and number of HF educator contacts after discharge. The number of completed checklists can be collected in the hospital EHR. The participating nursing organizations will collect the number of HF education sessions.

Data management

The PI and an assisting DMP coordinator will collect and enter data. All patient data is coded and pseudonymized. In pseudonymized data, we replace identifying particulars by an artificial identifier (i.e. a pseudonym). The list with pseudonyms, along with all other data is password-protected and stored in a secure encrypted cloud-drive (KU Leuven J-Drive). All other authors will have full access to the coded data (including the statistical reports and tables) in the study and will be able to take responsibility for the integrity of the data and the accuracy of the data analysis.

Data analysis

We will perform descriptive statistics regarding the baseline sociodemographic variables of patients with a HF nurse consultation. We will longitudinally plot all other outcomes measured at population level during the study. We will use chi-square tests to compare self-efficacy outcomes for GPs and HF patients who have a HF nurse contact. This is a descriptive study, hence we provide no sample size analysis. As stated previously, the goal is to study the implementation process, not the effectiveness of various interventions. Because of its descriptive nature, we plan to cautiously interpret the results.

Ethics

Before the study start, we will present the participating GPs with an informed consent form that outlines the intervention and the purpose of the study. Additionally, the HF educator will inform all the patients who receive an education session about the study and ask for informed consent. It is impossible to collect informed consents at the regional level (hospitalizations, echocardiographies, specialist consultations …), although this is not an issue since the data are aggregated and anonymous. We received approval from the University Hospitals Leuven Ethics Committee in September 2019 (S62838).

Conditions
Heart Failure
Being tested
Improved primary care HF diagnostics, Heart Failure education, Structured transitional protocol planning post-discharge care
Keywords
Primary Care, Community Care, General Practice, Self-management, Education, Transitional intervention, Chronic Care, Natriuretic Peptides, Audit and feedback, Electronic Health Record, GP training
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Improved primary care HF diagnosticsOther

    Reimbursement of natriuretic peptide testing for participating general practitioners (GPs) Audit and feedback in GPs EHR

  • Heart Failure educationOther

    Reimbursement of heart failure education for patients at risk. Web-based training for participating general practitioners

  • Structured transitional protocol planning post-discharge careOther

    Checklist-supported discharge protocol for HF patients including telephone contact with patients' general practitioners and a contact with the HF educator

Study groups in NCT04334447
Study groupRoleWhat they receive
Intervention Group PatientsExperimentalAll HF patients that experience a HF education session
Receives: Other: Improved primary care HF diagnostics; Other: Heart Failure education; Other: Structured transitional protocol planning post-discharge care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Yearly HF hospitalizations

    Measured: Three years

Secondary outcomes (4)
  1. Yearly cardiology consultations

    Measured: Three years

  2. Yearly echocardiographies

    Measured: Three years

  3. Registered HF diagnoses in the EHR

    Measured: Three years

  4. HF self-efficacy: EHFScBS-9 questionnaire

    Patient self-efficacy as measured by the EHFScBS-9 questionnaire

    Measured: At baseline and after 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Apr 2020
  2. Study start4 Nov 2019
  3. Primary completion31 Dec 2021 (estimated)
  4. Study completion31 Jul 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04334447
Sponsor's protocol ID
S68238
Status last verified
Apr 2020
First submitted
2 Apr 2020
Last updated
6 Apr 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Raat W, Smeets M, Van Pottelbergh G, Van de Putte M, Janssens S, Vaes B. Implementing heart failure disease management in primary care: a mixed-methods analysis of the IMPACT-B study. BMJ Open. 2025 Jul 20;15(7):e093414. doi: 10.1136/bmjopen-2024-093414.

    PubMed 40685241
  • Raat W, Smeets M, Van Pottelbergh G, Van de Putte M, Janssens S, Vaes B. Implementing standards of care for heart failure patients in general practice - the IMPACT-B study protocol. Acta Cardiol. 2021 Jul;76(5):486-493. doi: 10.1080/00015385.2020.1844504. Epub 2020 Nov 9.

    PubMed 33161831

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Improved primary care HF diagnostics, Heart Failure education and Structured transitional protocol planning post-discharge care in people with Heart Failure, run by KU Leuven at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Willem Raat (016 37 66 21, willem.raat@kuleuven.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Yearly HF hospitalizations (time frame: Three years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04334447, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in